REFERENCES
1. Akinyemiju T, Abera S, Ahmed M, Alam N. Global burden of disease liver cancer collaboration. the burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 2017;3:1683-91.
2. Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2015;45:884-91.
3. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
4. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-80.
5. Murray LJ, Dawson LA. Advances in stereotactic body radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol 2017;27:247-55.
6. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, et al. Sequential phase I and II trial stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631-9.
7. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012;118:5424-31.
8. Durand-Labrunie J, Baumann AS, Ayav A, Laurent V, Boleslawski E, et al. Curative irradiation treatment of hepatocellular carcinoma: a multicenter phase 2 trial. Int J Radiat Oncol Biol Phys 2020;107:116-25.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR, Tang GJ, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
10. Michel R, Françoise I, Laure P, Anouchka M, Guillaume P, et al. Dose to organ at risk and dose prescription in liver SBRT. Rep Pract Oncol Radiother 2017;22:96-102.
11. Ohri N, Tomé WA, Méndez Romero A, Miften M, Ten Haken RK, et al. Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys 2018. doi: 10.1016/j.ijrobp.2017.12.288
12. Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol 2014;53:399-04.
13. Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014;111:412-7.
14. Rosenberg SA, Henke LE, Shaverdian N, Mittauer K, Wojcieszynski AP, et al. A multi-institutional experience of MR-guided liver stereotactic body radiation therapy. Adv Radiat Oncol 2018;4:142-9.
15. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, et al. Multi-institutional phase ii study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016;34:460-8.
16. Cheung TT, Poon RT, Yuen WK, Chok KS, Jenkins CR, et al. Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. Ann Surg 2013;257:506-11.
17. Yoon YI, Kim KH, Kang SH, Kim WJ, Shin MH, et al. Pure laparoscopic versus open right hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a propensity score matched analysis. Ann Surg 2017;265:856-63.
